The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54 Gy to the pelvis | Zendy

G.L. Jensen | Zendy; Sameer Jhavar | Zendy; Chul S. Ha | Zendy; Kendall Hammonds | Zendy; Gregory P. Swanson | Zendy

Open Access

The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54 Gy to the pelvis

Author(s) -

G.L. Jensen,

Sameer Jhavar,

Chul S. Ha,

Kendall Hammonds,

Gregory P. Swanson

Publication year - 2022

Publication title -

clinical and translational radiation oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.336

H-Index - 15

ISSN - 2405-6308

DOI - 10.1016/j.ctro.2022.06.008

Subject(s) - medicine , prostate cancer , prostatectomy , quality of life (healthcare) , radiation therapy , urinary incontinence , urology , brachytherapy , endometrial cancer , cancer , surgery , nursing

Elective pelvic lymph node radiotherapy (PLNRT) in prostate cancer is often omitted from definitive (n = 267) and post prostatectomy (n = 160) radiotherapy (RT) due to concerns regarding toxicity and efficacy. Data comparing patient-reported outcome measures (PROMs) with or without PLNRT is limited. Our long-term supposition is that PLNRT, particularly to higher doses afforded by IMRT, will decrease pelvic failure rate in select patients. We aim to establish the impact of two different PLNRT doses on long term quality of life (QOL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research